David W. Osborne, Chief Technical Officer at Arcutis Biotherapeutics, Inc. (ARQT), sold 2,005 shares at $16.17 ($32K) on 2023-02-28, disclosed to the SEC on 2023-03-02.
Scheduled sale ($32k) by Chief Technical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.17 | 792 | $13K | 40.0% |
| 2 | $15.82 | 1,198 | $19K | 59.2% |
| 3 | $16.52 | 15 | $248 | 0.8% |
| Total | $15.96 avg | 2,005 | $32K | 100% |
| Filing → |
| ARQT | SELL | 2022-04-21 | $45K | — | Filing → |
| ARQT | SELL | 2022-03-07 | $14K | — | Filing → |
| ARQT | SELL | 2022-03-03 | $14K | — | Filing → |